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Rhinitis is defined as inflammation of the nasal 
membranes1 and is characterized by a symptom 
complex that consists of any combination of the 
following: sneezing, nasal congestion, nasal 
itching, and rhinorrhea.2 The eyes, ears, sinuses, 
and throat can also be involved. 
Allergic rhinitis is the most common cause of 
rhinitis. It is an extremely common condition, 
affecting approximately 20% of the population. 
Systemic effects, including fatigue, sleepiness, 
and malaise, can occur from the inflammatory 
response. These symptoms often contribute to 
impaired quality of life.3,4  
Classification of allergic rhinitis: 
The Allergic Rhinitis and its Impact on Asthma 
(ARIA) group in conjunction with the World 
Health Organization (WHO), has revised the 
classification of AR. This classification includes a 
measurement of the frequency and duration of 
symptoms. Intermittent AR is defined as 
experiencing symptoms for < 4 days/week or < 4 
consecutive weeks. Persistent AR is termed as 
symptoms occurring for more than 4 days/week 
and more than 4 consecutive weeks. Additionally, 
a severity scale of mild to moderate-severe was 
included in the revised classification.5  
 
Intermittent 
allergic 
rhinitis
PER
Mild
Normal sleep; no 
impairment of daily 
leisure, or sport 
activities; normal work 
or school; no 
troublesome symptoms
Moderate-severe
One or more of the 
following: abnormal sleep; 
impairment of daily leisure, 
or sport activities; 
abnormal work or school;  
troublesome symptoms
≤4 days/week
or ≤ 4 weeks
>4 days/week
and > 4 weeks
Symptoms
Rhinorrhea
Blocked nose
Itchy nose
Sneezing
Itchy eyes
 
 
Figure 1. Allergic Rhinitis and its Impact on Asthma (ARIA). Dark lines show that moderate-to-severe 
symptoms occur most often in persistent allergic rhinitis (PER) with milder symptoms in intermittent allergic 
rhinitis. Quoted from Bousquet et. al (2001)6. 
 
Pathophysiology 
Allergic rhinitis involves inflammation of the 
mucous membranes of the nose, eyes, Eustachian 
tubes, middle ear, sinuses, and pharynx. The nose 
invariably is involved, and the other organs are 
affected in certain individuals. Inflammation of the 
mucous membranes is characterized by a complex 
interaction of inflammatory mediators but 
ultimately is triggered by an immunoglobulin E 
(IgE)–mediated response to an extrinsic protein.5  
The tendency to develop allergic, or IgE-mediated, 
reactions to extrinsic allergen has a genetic 
component. In susceptible individuals, exposure to 
certain foreign proteins leads to allergic 
sensitization, which is characterized by the 
production of specific IgE directed against these 
proteins. This specific IgE coats the surface of mast 
cells, which are present in the nasal mucosa. When 
the specific protein (e.g., a specific pollen grain) is 
inhaled into the nose, it can bind to the IgE on the 
Review article 
Deraz 
 4
mast cells, leading to immediate and delayed 
release of a number of mediators.7-9  
The mediators that are immediately released include 
histamine, tryptase, chymase, kinins, and heparin. 
The mast cells quickly synthesize other mediators, 
including leukotrienes and prostaglandin D2.10-12 
These mediators, via various interactions, 
ultimately lead to the symptoms of allergic   rhinitis 
(nasal congestion, sneezing, itching, redness, 
tearing, swelling, ear pressure, postnasal drip). 
Mucous glands are stimulated, leading to increased 
secretions. Vascular permeability is increased, 
leading to plasma exudation. Vasodilatation occurs, 
leading to congestion and pressure. Sensory nerves 
are stimulated, leading to sneezing and itching. All 
of these events can occur in minutes; hence, this 
reaction is called the early, or immediate, phase of 
the reaction. Over 4-8 hours, these mediators, 
through a complex interplay of events, lead to the 
recruitment of other inflammatory cells to the 
mucosa, such as neutrophils, eosinophils, 
lymphocytes, and macrophages. This results in 
continued inflammation, termed the late-phase 
response. The symptoms of the late-phase response 
are similar to those of the early phase, but less 
sneezing and itching and more congestion and 
mucus production tend to occur. The late phase may 
persist for hours or days.13  
When studying the allergic nose, several aspects 
must be taken into consideration: the genetic 
background of the patient, various environmental 
factors (antigens, air pollution, climate), and the 
peculiar characteristics of the nose itself including 
its anatomy (total surface area: 150 cm, volume: 
15 ml) and histology including the epithelium 
(ciliated, non ciliated, pseudostratified, columnar, 
and goblet cells), mucus, immunocompetent cells, 
lamina propria, basement membrane, blood supply, 
and nerves and neurotransmitters.14 
 
Immunopathogenesis of allergic rhinitis 
Allergic rhinitis is an increasing problem for which 
new and exciting therapies are being developed. 
These can be understood through an appreciation of 
the newer concepts of pathogenesis of allergic 
rhinitis. Allergen induces Th2 lymphocyte 
proliferation in persons with allergies with the 
release of their characteristic combination of 
cytokines including IL-3, IL-4, IL-5, IL-9, IL-10, 
and IL-13. These substances promote IgE and mast 
cell production. Mucosal mast cells that produce 
IL-4, IL-5, IL-6, and tryptase proliferate in the 
allergic epithelium. Inflammatory mediators and 
cytokines upregulate endothelial cell adhesion 
markers such as the vascular cell adhesion 
molecule-1. Chemoattractants including eotaxin, 
IL-5, and RANTES lead to the characteristic 
infiltration by eosinophils, basophils, Th2 
lymphocytes, and mast cells in chronic allergic 
rhinitis.15
 
 
Figure 2. Cell and mediator pathways underlying the pathogenesis of allergic rhinitis. Quoted from Holgate 
and Broide (2003)16 
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A high degree of cell-to-cell communication 
is needed to orchestrate this inflammatory 
immune response. A variety of cytokines and 
adhesion receptors seem to play an important role 
in the allergic reaction. Proinflammatory 
cytokines such as IL-1, IL-8 and TNF-α (tumor 
necrosis factor-alpha) can be detected in nasal 
secretions and mucosa. The increased expression 
of adhesion receptors in mucosal specimens of 
patients with allergic rhinitis points to their role in 
regulating the cellular migration and probably 
represents a key event in allergic inflammation. E-
selectin receptor was strongly upregulated by IL-
1β, TNF-α and allergen. The induction due to 
allergen exposure of the mucosa was markedly 
inhibited by soluble cytokine receptors (sIL-IR, 
TNF-BP) or by a receptor antagonist (IL-1 ra) and 
prednisolone. These findings indicate that 
proinflammatory cytokines may be key factors for 
the upregulation of adhesion processes in human 
nasal mucosa and the activation of various cell 
populations involved in the allergic inflammation. 
They, therefore, represent a main target for new 
therapeutic strategies.15  
The type and amount of inflammation in 
allergic rhinitis are regulated by cytokines. 
Therefore, the production of the Th2-cytokines, 
IL-4, IL-5, IL-13, of the Th1-cytokines, IFN-γ and 
IL-12 and of the regulatory cytokine IL-10 that is 
capable of down regulating their synthesis was 
investigated. It was found that the production of 
IL-4, IL-5, and IL-13 was significantly elevated in 
allergics; the number of IL-12 and IFN-γ-
producing cells was significantly elevated as well. 
IL-10 was also significantly higher in allergics. 
This investigation of cytokine production during 
natural allergen exposure demonstrates that the 
synthesis of both Th2- and Th1-cytokines is 
increased in allergic rhinitis.17  
Allergic rhinitis represents a persistent 
inflammation in terms of activation of eosinophils 
and constant upregulation of the proinflammatory 
cytokine IL-1beta in the pollen season and 
thereafter. Persistent inflammation may 
furthermore lead to the dysregulation of local 
cellular immunity by reducing the number and 
activity of neutrophils on the mucosal surface.18  
In allergic rhinitis, there is epithelial mast cell 
accumulation and tissue infiltration by 
eosinophils. Activation of these cells can be 
observed by electron microscopy and by elevated 
levels of tryptase and eosinophil cationic protein 
in nasal lavage fluid. Seasonal increases in the 
antigen presenting cell (Langerhans' cell) are also 
evident. Investigations into the mechanisms 
involved in cell accumulation and activation 
reveal upregulation of leukocyte endothelial 
adhesion molecules and an increase in interleukin-
4 (IL-4) in naturally occurring rhinitis, while 
mRNA for IL-4, IL-5 and granulocyte 
macrophage colony stimulating factor activity and 
lavage tumor necrosis factor-alpha (TNF alpha) 
levels are increased following local allergen 
challenge. These cytokines may be derived from a 
variety of sources, including mast cells, 
eosinophils and T-lymphocytes, and contribute to 
the underlying inflammatory process in rhinitis.19 
 Allergic rhinitis is a particularly good model 
for studies of cytokine production in vivo, the 
occurrence of the cytokines IL-4, IL-5. IL-10 and 
IFN-gamma as well as the soluble IL-4 receptor in 
nasal lavage fluid were assayed. It was found that 
IL-4 levels in patients with seasonal allergic 
rhinitis were markedly increased in comparison 
with those in non-atopic patients or in atopic 
patients before the start of the pollen season. The 
IL-4/IFN-gamma ratios were significantly higher 
in atopic than in non atopic patients and it further 
increased in atopic patients during the season. In 
addition to IL-4, elevated levels of IL-10 were 
observed in association with seasonal rhinitis. 
Following treatment with a topical steroid, there 
was a statistically significant increase of the levels 
of soluble IL-4 receptor. These findings indicate 
that non atopic and atopic individuals react to 
pollen exposure with distinct cytokine patterns in 
agreement with the Thl/ Th2 concept.20,21 
 
Role of Cysteinyl leukotrienes in allergic 
rhinitis 
Cysteinyl leukotrienes (CysLTs) are a family of 
inflammatory lipid mediators synthesized from 
arachidonic acid by a variety of cells, including 
mast cells, eosinophils, basophils, and 
macrophages. CysLTs play a multi-functional role 
as mediators in allergic rhinitis (AR) as follows: 
CysLTs are released from inflammatory cells that 
participate in allergic rhinitis, receptors for 
CysLTs are located in nasal tissue, CysLTs are 
increased in patients with AR and are released 
following allergen exposure, administration of 
CysLTs reproduces the symptoms of AR, CysLTs 
play an important role in the maturation, as well 
as tissue recruitment of inflammatory cells and a 
complex inter-regulation between CysLTs and a 
variety of other inflammatory mediators exists.23 
CysLTs are synthesized via 5-lipoxygenase 
metabolism of arachidonic acid by mast cells and 
basophils during the early-phase response to 
antigen and by eosinophils and macrophages 
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during the late phase. The cysLT levels in nasal 
secretions are elevated after short-term allergen 
instillation and in allergy season in patients with 
allergic rhinitis. These lipid mediators act locally 
and systemically by interacting with receptors, 
particularly the cysLT1 receptor, on target cells. 
CysLTs promote allergic inflammation by 
enhancing immune responses and the production, 
adhesion, migration, and survival of inflammatory 
cells such as eosinophils. They also increase the 
generation of an array of other proinflammatory 
mediators such as cytokines, which in turn 
increase the production of and receptors for 
cysLTs. Clinical trials have demonstrated that 
leukotriene receptor antagonists (LTRAs) have 
significant but modest efficacy as single agents 
but additive efficacy when used with other classes 
of agents.24,25  
As our understanding of the basic 
pathophysiologic features of allergic rhinitis 
continues to increase, the development of new 
diagnostic and treatment strategies may allow for 
more effective modulation of the immune system, 
the atopic disease process, and the associated 
morbidity. The production of allergen-specific 
IgE, activation of mucosal mast cells and the 
recruitment and activation of effector leukocytes 
provide potential therapeutic targets, including 
selective inhibition of cytokines, adhesion 
molecules and signaling pathways. Blockade of 
IgE, using monoclonal antibodies and vaccine 
strategies is a new approach for interrupting the 
allergic cascade, whereas the use of recombinant 
mutated allergens, peptides and DNA 
oligonucleotides will lead to improved efficacy 
and reduced side effects of immunotherapy for 
tolerance induction.16 
 
 
Figure 3. Potential CysLT signaling pathways in inflammatory cells in allergic rhinitis. 
Adopted from Figueroa et al. (2003). 
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